tradingkey.logo

Impact Biomedical Inc

IBO
查看詳細走勢圖
0.511USD
-0.051-9.03%
收盤 12/24, 13:00美東報價延遲15分鐘
6.23M總市值
虧損本益比TTM

Impact Biomedical Inc

0.511
-0.051-9.03%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

-9.03%

5天

+16.11%

1月

+18.84%

6月

-39.17%

今年開始到現在

-64.76%

1年

-64.27%

查看詳細走勢圖

TradingKey Impact Biomedical Inc股票評分

單位: USD 更新時間: 2025-10-27

操作建議

當前估值合理,機構持股佔比非常高,目前股價在壓力位和支撐位之間,可以做區間波段操作。

Impact Biomedical Inc評分

相關信息

行業排名
305 / 501
全市場排名
591 / 4682
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 0 分析師
--
評級
0.000
目標均價
0.00%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Impact Biomedical Inc亮點

亮點風險
Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值高估
公司最新PE估值-0.17,處於3年歷史高位
機構加倉
最新機構持股508.04K股,環比增加15.77%

Impact Biomedical Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Impact Biomedical Inc簡介

Impact Biomedical, Inc. is a biotechnology company engaged in discovering, developing, and patenting healthcare solutions. It discovers, confirms, and patents science and technologies, which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships. It has several technologies that are in continuing development, which include Linebacker, Laetose, Functional Fragrance Formulation (3F), Equivir/Equivir G, and Celios. Linebacker is a platform of small molecule electrophilically enhanced polyphenol compounds with potential application in oncology (solid tumors), inflammatory disorders, and neurology. Laetose technology is derived from a combination of multiple sugars independently with myo-inositol. 3F is a suite of organic functional fragrances. Celios is an air purification technology. It also evaluates additional technologies.
公司代碼IBO
公司Impact Biomedical Inc
CEOHeuszel (Frank D)
網址https://www.impactbiomedinc.com/

常見問題

Impact Biomedical Inc(IBO)的當前股價是多少?

Impact Biomedical Inc(IBO)的當前股價是 0.511。

Impact Biomedical Inc 的股票代碼是什麼?

Impact Biomedical Inc的股票代碼是IBO。

Impact Biomedical Inc股票的52週最高點是多少?

Impact Biomedical Inc股票的52週最高點是6.170。

Impact Biomedical Inc股票的52週最低點是多少?

Impact Biomedical Inc股票的52週最低點是0.362。

Impact Biomedical Inc的市值是多少?

Impact Biomedical Inc的市值是6.23M。

Impact Biomedical Inc的淨利潤是多少?

Impact Biomedical Inc的淨利潤為-24.71M。

現在Impact Biomedical Inc(IBO)的股票是買入、持有還是賣出?

根據分析師評級,Impact Biomedical Inc(IBO)的總體評級為--,目標價格為--。

Impact Biomedical Inc(IBO)股票的每股收益(EPS TTM)是多少

Impact Biomedical Inc(IBO)股票的每股收益(EPS TTM)是-3.932。
KeyAI